annual general meeting review, page-31

Thanks K9 - kind of you to say so :-)

1212 > if you're reading this..
a proactiveinvestors article of August 26th 2013 estimates the cost per unit for CardioCel is at $1,200 each.

However, the estimate of unit-sales you were given at the agm is massively different to RBS Morgan's research notes from that article - google 'cardiocel cost' to find it.

With Lee saying "He thought the market for cardiocel would take about 3 yrs to mature and he expected about 3 million sales of cardiocel by then."
...I'm thinking he might have meant that in terms of $3m Revenue...rather than 3m Units (@ $1,200 each that's $3.6Bn)
Big Difference, considering the theme of the meeting seemed to be that of downplaying it's potential - including the expected timeframe for FDA approval being later than we'd first considered.
Let's face it, the TOTAL CHD+AdultValveRepair market is stated at $1.15Bn so $3.6Bn would be wayyy off the mark...

I reckon they should have their own broker/analyst do a proper report for the market now, or at least a BoardroomRadio interview with all the right questions posed to someone such as Lee...together with a current trading update and progress of the sales teams.
Just my thoughts...